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“Once	the	development	was	ended,	 the	 founts	of	growth	and	regeneration	of	 the	axons	and	
dendrites	dried	up	irrevocably.	In	the	adult	centers,	the	nerve	paths	are	something	fixed,	ended,	and	
immutable.	Everything	may	die,	nothing	may	be	regenerated”.	This	“no	new	adult	brain	cells”	dogma	
expressed	 by	 the	 great	 Spanish	 neuroscientist	 Santiago	 Ramón	 y	 Cajal	 a	 century	 ago	 (1).	 Despite	
challenges	to	the	dogma	in	the	1960s,	most	of	which	were	greeted	with	skepticism,	it	remained	the	
prevailing	view	up	to	the	1980s	when	more	convincing	results	reported	the	genesis	of		new	brain	cells	
over	the	entire	lifespan	of	mammals	(2).		
A	Medline	search	of	the	term	“neurogenesis”	in	2017	retrieved	more	than	22,800	papers	with	
an	exponential	increase	starting	from	early	90s.	Among	them,	the	entry	“adult	neurogenesis”	occurs	in	
over	8,000	papers	from	the	beginning	of	the	21st	century.	These	numbers	underpin	the	growing	interest	
in	 this	 topic	 and	 the	possible	 therapeutic	exploitation	of	 adult	neurogenesis	 for	 currently	 incurable	
brain	pathologies.	Some	confusion	may	arise	in	the	use	of	the	term	neurogenesis,	since	it	sometimes	
broadly	refers	to	the	generation	of	both	new	neurons	and	glial	cells	from	multipotent	precursors.	To	
avoid	any	misunderstandings,	in	the	present	Special	Issue	of	Biochemical	Pharmacology	we	refer	to	a	
second	more	restricted	meaning,	specifically	the	generation	of	new	neurons	from	resident	neural	stem	
cells	(NSCs)	or	multipotent	progenitors	(2).	
Two	main	regions	in	the	brain	show	continuing	neurogenesis	during	adult	life:	the	subventricular	
zone	(SVZ)	of	the	lateral	ventricles	and	the	subgranular	zone	(SGZ)	of	the	hippocampus	(3,	4).	Within	
these	 two	areas,	NSCs	undergo	proliferation,	 asymmetric	division,	migration	and	differentiation.	As	
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described	in	several	contributions	in	this	Special	Issue	(2,	5,	6),	these	processes	are	affected	by	central	
nervous	system	(CNS)	injuries,	neurodegenerative	diseases	and	depression-like	pathologies.		
New	 technologies	 and	 technical	 approaches	 have	 allowed	 the	 identification	 of	 additional	
parenchymal	pools	of	progenitors	endowed	with	 the	 intrinsic	 ability	 to	generate	new	neurons.	 The	
logical	 subsequent	 step	 of	 this	 discovery	 is	 to	 understand	 how	 their	 capacity	 to	 generate	 specific	
neuronal	 subtypes	 can	be	 controlled	 and	driven	 to	 replace	 lost	 cells	 due	 to	pathological	 events.	 In	
particular,	the	possibility	of	re-direct	resident	NG2	cells,	astrocytes,	and	retinal	Müller	glia	to	produce	
functional	neurons	has	been	extensively	investigated	over	the	past	few	decades.	The	exhaustive	review	
by	Boda	and	coworkers	(7),	describes	several	intrinsic	and	extrinsic	factors	that	can	be	manipulated	to	
foster	the	neurogenic	conversion	of	glia.	In	this	respect,	the	most	innovative	and	promising	strategy	to	
avoid	the	potential	risks	of	introducing	exogenous	genetic	material	is	represented	by	cocktails	of	small	
molecules	which	have	proven	able	to	successfully	reprogram	reactive	astrocytes	directly	to	functional	
neurons	 (8-10).	This	direct	 reprogramming	towards	 the	neuronal	 lineage	without	passing	 through	a	
dedifferentiated	 progenitor	 stage	 reduces	 the	 risks	 for	 uncontrolled	 proliferation	 and	 tumor	
generation.		
Although	the	neurogenic	potential	of	NG2	cells	has	been	extensively	studied	(9,	11),	they	are	
primarily	 considered	 as	 the	 major	 source	 of	 new	 oligodendrocytes	 that	 potentially	 can	 lead	 to		
remyelination	in	demyelinating	disorders,	like	multiple	sclerosis	(12).	Accordingly,	considerable	effort	
has	been	focused	on	the	development	of	new	strategies	to	potentiate	their	proliferation	and	neuronal	
differentiation	via	the	manipulation	of	a	variety	of	signaling	molecules,	growth	factors,	hormones	and	
even	neurotransmitters	(11).		
The	major	challenge	is	that	NSCs	react	to	both	acute	events	and	chronic	brain	disorders	with	
increased	proliferation	and	generation	of	neuroblasts,	which	encounter	difficulties	to	fully	integrate	in	
existing	networks.	Thus,	besides	promoting	the	neurogenic	conversion	of	NSCs,	a	full	understanding	of	
the	 permissive	 and	 inhibitory	 factors	 in	 the	 extracellular	 milieu	 is	 mandatory.	 As	 for	 many	 other	
processes	in	the	human	body,	various	physiological	conditions,	such	as	sex	and	age	(13,	14),	and	daily	
life	activities,	such	as	nutrition	(15)	can	profoundly	influence	adult	neurogenesis.		
In	this	respect,	the	sex	dimorphism	of	the	brain	and	its	effect	on	NSC	functions	are	addressed	in	
this	 Special	 Issue	by	Heberden	and	colleagues	 (13).	 Indeed,	male	and	 female	 sex	 steroid	hormones	
produced	by	the	gonads	can	reach	the	brain	through	the	circulation	or	they	can	be	directly	synthesized	
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in	the	CNS.	Here	they	exert	both	peculiar	and	common	functions:	estrogens	stimulate	cell	proliferation,	
while	 androgens	 and	 progestogens	 protect	 cells	 from	 apoptosis,	 increase	 cell	 survival	 and	 favor	
neuronal	renewal.	In	parallel,	all	the	three	classes	exert	positive	effects	on	NSC	differentiation.	More	
importantly,	they	can	also	help	in	counteracting	the	deleterious	effects	of	stroke	or	ischemia.	Regarding	
possible	 clinical	 applications,	 promising	 results	 have	 been	obtained	 in	 preclinical	 animal	 trials	 after	
administration	 of	 some	 phytochemicals	 (i.e.,	 soy	 phytoestrogens,	 naringenin,	 and	 resveratrol);	
however,	 in	humans,	observational	and	interventional	studies	 led	to	contrasting	results.	 In	addition,	
the	 effects	 of	 several	 synthetic	 steroid	 agonists	 (i.e.,	 diarylpropionitrile,	 propylpyrazole	 triol	 and	
tamoxifen),	have	also	been	investigated	(13).	
As	noted,	another	interesting	aspect	of	everyday	life	that	needs	to	be	taken	into	account	when	
studying	adult	neurogenesis	is	the	nutritional	intake.	Indeed,	as	described	by	Fidaleo	and	coworkers	
(15),	excess	nutrients	can	lead	to	an	impairment	of	neurogenesis	by	premature	exhaustion	of	the	NSC	
pool,	 while	 calorie	 restriction	 has	 the	 opposite	 effect.	 Interestingly,	 these	 effects	 are	mediated	 by	
several	nutrient-sensing	cascades	(i.e.,	insulin,	mTOR,	CREB,	Sirtuin)	that	can	be	potentially	modulated	
by	already	approved	or	experimental	drugs	and	may	have	important	clinical	applications	in	metabolic	
diseases,	aging	and	acute	brain	damage	(15).		
Due	 to	 the	 recent	 significant	 increase	 in	 the	 average	 life	 expectancy,	 understanding	 the	
molecular	mechanisms	of	aging	has	become	of	primary	importance,	as	also	demonstrated	by	the	huge	
amount	 of	 funds	 allocated	 to	 this	 research	 field.	 The	 current	 knowledge	 regarding	 the	 correlation	
between	adult	neurogenesis	and	aging	is	covered	in	the	review	by	Apple	and	colleagues	(14).	During	
aging,	NSCs	(either	in	the	SVZ	or	in	SGZ)	and	their	progenitors	exhibit	reduced	proliferation	and	neuron	
production,	which	is	thought	to	contribute	to	age-associated	cognitive	impairment	and	reduced	brain	
plasticity	 (13,	 15).	 Interestingly,	 both	 hormone	 therapy	 and	 calorie	 restriction	 can	 be	 envisaged	 as	
strategies	to	stimulate	neurogenesis	and	resolve	cognitive	decline	in	the	elderly.	
In	 addition	 to	 the	 defects	 in	 adult	 neurogenesis	 that	 have	 been	 detected	 in	 several	 brain	
pathologies	(2,	5,	6),	marketed	drugs	and	drugs	of	abuse	can	have	a	significant	impact	on	the	ability	of	
the	brain	to	generate	new	neurons.	As	comprehensively	discussed	by	Eliwa	and	coworkers	(16),	various	
classes	of	monoaminergic	antidepressants	(including	tricyclics,	monoamine	oxidase	inhibitors,	selective	
serotonin	 reuptake	 inhibitors	 and	 norepinephrine	 reuptake	 inhibitors)	 increase	 adult	 hippocampal	
neurogenesis	 by	 acting	 predominantly	 on	 cell	 proliferation,	 maturation,	 and	 survival	 (16).	 More	
specifically,	chronic	antidepressant	treatment	can	stimulate	NSC	proliferation	and	promote	the	survival	
of	adult-born	neurons	in	rodents	and	primates.	These	findings	are	of	immediate	clinical	relevance,	since	
antidepressant	drugs	increase	the	number	of	progenitor	cells	in	the	SGZ	of	depressed	patients	as	well,	
leading	to	the	suggestion	that	this	effect	could	contribute	to	their	efficacy.	Less	clear	results	have	been	
obtained	with	new	innovative	therapies,	e.g.,	ketamine,	that	act	via	non-monoaminergic	mechanisms	
(16).	
As	reviewed	by	Castilla-Ortega	and	colleagues	(17),	the	impact	of	cocaine	on	adult	hippocampal	
neurogenesis	is	a	complex	phenomenon	which	involves,	besides	endocannabinoids,	a	number	of	other	
neurobiological	 factors.	 In	 particular,	 these	 authors	 have	 identified	 two	 cognitive	 events	 that	 link	
cocaine	 assumption	 and	 hippocampal	 functions:	 i)	 the	 formation	 of	 robust	 memories	 for	 cocaine-
stimuli	 associations	 that	may	 be	 established	 during	 the	 initial	 experiences	with	 the	 drug,	 and	 that	
contribute	 to	 drug	 craving,	 and	 ii)	 the	 global	 cognitive	 decline	 that	 emerges	 after	 chronic	 cocaine	
exposure	and	impedes	the	acquisition	of	new	and	beneficial	information.	Thus,	the	negative	outcomes	
of	 drugs	 of	 abuse	 can	 be	 manifest	 through	 the	 persistent	 impairment	 of	 adult	 hippocampal	
neurogenesis,	with	a	dramatic	impact	on	cocaine	addiction	(17).	
As	 is	 evident	 from	 the	 papers	mentioned,	 the	 biomedical	 research	 community	 is	 only	 now	
beginning	 to	 fully	 comprehend	 the	 importance	 and	 contribution	 of	 adult	 neurogenesis	 to	 brain	
physiology	and	pathology,	and	how	to	foster	its	beneficial	outcomes	by	reducing	in	parallel	its	negative	
aspects.	 In	 this	 respect,	 in	 this	 Special	 Issue	 we	 have	 also	 deemed	 interesting	 to	 explore	 some	
innovative	and	unconventional	approaches.	The	first	is	represented	by	miRNAs,	whose	discovery	has	
profoundly	modified	the	comprehension	of	 the	modulation	of	biological	processes	at	 the	molecular	
level.	In	their	article,	Saraiva	and	colleagues	depict	a	scenario	where	miRNAs	play	a	major	role	in	adult	
neurogenesis,	and	also	in	neurodegenerative	processes	suggesting	that	therapeutic	approaches	based	
on	miRNAs	represents	are	a	promising	avenue	for	future	drug	discovery	(5).	
From	an	historical	perspective,	the	traditional	medicine	systems	which	have	represented	the	
only	therapeutic	option	in	Far	Eastern	countries	such	as	China,	India	and	Pakistan	for	centuries	(18)	also	
appear	to	involve	aspects	of	neurogenesis.	In	Traditional	Chinese	Medicine	(TCM)	system	acupuncture,	
phytotherapy	 and	 other	 techniques	 are	 widely	 used	 to	 guarantee	 the	 overall	 well-being	 of	 the	
organism,	 in	 this	 instance	 humans.	 The	 principles	 of	 TCM	 lie	 in	 the	 philosophical	 approach	 to	 the	
universe,	which	includes	the	concepts	of	Yin	and	Yang	equilibrium	and	the	optimal	flow	of	the	energy	
flux	termed	Qi.	These	concepts	represent	the	basis	for	TCM	practitioners	to	select	the	best	therapeutic	
approach	 for	 the	 individual	 patient,	 personalized	medicine	 from	 a	 precomputer	 age.	 Following	 the	
global	 interest	 in	 better	 understanding	 TCM	 considerable	 efforts	 have	 been	 applied	 to	 analyse	 the	
effects	of	acupuncture	and	Chinese	phytotherapy	in	“Western”	scientific,	e.g.,	molecular,	terms.	This	
has	 led	to	 interesting	results	 in	the	field	of	neurogenesis,	as	described	for	acupuncture	by	Shin	and	
colleagues	(5).	Insertion	and	manipulation	of	needles	in	specific	acupoints	leads	to	the	local	release	of	
a	plethora	of	neurotransmitters	and	neuromodulators,	including	growth	factors,	which	in	turn	sustain	
neurogenesis.	 Interestingly,	 based	 on	 available	 data	 in	 neurological	 diseases,	 it	would	 be	 better	 to	
choose	the	best	acupoint	to	be	stimulated	by	evaluating	its	ability	to	promote	growth	factor	release,	
instead	 of	 considering	 its	 “traditional”	 characteristics	 (5).	 Additionally,	 various	 plants	 traditionally	
employed	 to	 restore	 brain	 capacities	 in	 the	 elderly	 behave	 as	 potent	 modulators	 of	 endogenous	
neurogenesis,	 as	 reviewed	 by	 Zheng	 and	 coworkers	 (19).	 Traditional	 medicine	 approaches	 should	
therefore	 be	 taken	 into	 consideration	 as	 possible	 complementary	 supports	 to	 inform	 other	 pro-
neurogenic	pharmacological	approaches	
This	Special	Issue	depicts	an	overview	of	currently	available	knowledge	on	the	modulation	of	
neurogenesis	in	the	adult	brain,	by	endogenous	signaling	pathways,	by	drugs	and/or	by	physiological	
and	 pathological	 conditions,	 with	 the	 ultimate	 aim	 of	 assessing	 whether	 a	 possible	 translation	 of	
experimental	 data	 on	 adult	 neurogenesis	 to	 patients	 remains	 an	 unattainable	 hope	 or	 whether	
encouraging	results	are	emerging.	
As	 Guest	 Editors	 of	 this	 Special	 Issue,	 our	 thanks	 go	 to	 all	 the	 colleagues	 that	 have	
enthusiastically	 accepted	 to	 participate	with	 their	manifold	 expertize.	We	 are	 also	 indebted	 to	 the	
Editorial	Staff	of	Biochemical	Pharmacology,	in	particular	Lynn	LeCount,	Jennifer	McNichols,	and	Mike	
Williams	for	their	support	in	helping	the	Editors	assemble	this	Special	issue.	
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